Euonine and wilforidine are biologically active Tripterygium wilfordii Hook. f. alkaloids. In this paper, a rapid and sensitive high-performance liquid chromatography -mass spectrometry (MS) method was developed and validated for the simultaneous determination of trace euonine and wilforidine in human plasma. An Oasisw mixed-mode cation-exchange polymeric sorbent was used for solid-phase extraction. The separation was carried out on a reversed-phase Zorbax Plus C 18 column (50 mm 3 2.1 mm, 1.8 mm) by using ammonium acetate (5 mmol/L)/acetonitrile (30/70, v/v) as the mobile phase at a flow rate of 0.7 mL/min. The quantification was carried out via ion trap MS in the positive selected ion monitoring mode using aconitine as an internal standard. Calibration curves showed good linearity ranging from 0.5 to 100.0 mg/L with correlation coefficient values >0.9990. The average recoveries of euonine and wilforidine ranged from 85.4 to 101.0% and 92.0 to 97.5%, respectively. The intra-and interday relative standard deviations were <8.7 and 12.9%, respectively. The limits of quantification for both euonine and wilforidine were 0.5 mg/L, which is suitable in the clinical pharmaceutical research of volunteer patients with rheumatoid arthritis.
Introduction
Tripterygium wilfordii Hook. f. (TW), a liana belonging to the winged euonymus family, is widely used in traditional Chinese medicine for treating diseases of various systems caused by dysimmunity, with good therapeutic effects (1 -5) . Euonine and wilforidine ( Figure 1 ) are the main biologically active components of TW (6) . Euonine exhibits marked depressant effects on humoral-mediated immunity using hemolytic reactions as indices (7) and demonstrates good antifeedant activity against the lepidopteran Spodoptera littoralis (8) . Wilforidine can inhibit the function of B-cells and the proliferation of peripheral blood mononuclear cells in lupus patients (9, 10) . Studies show that euonine and wilforidine have the potential to cure autoimmune diseases. Therefore, an analytical method should be developed to determine the residues in biological samples for pharmacokinetic studies.
However, pharmacokinetic studies on euonine and wilforidine in vivo are lacking. An accurate and sensitive analytical method is a prerequisite in conducting a series of pharmacokinetic studies. With the advent of atmospheric-pressure chemical ionization (APCI) and electrospray ionization (ESI), mass spectrometry (MS) has become a powerful analytical tool in pharmaceutical analysis because of its high sensitivity, selectivity and rapid analysis time (11 -16) . In combination with high-performance liquid chromatography (HPLC), MS is considered a superior alternative for residue analysis in biological samples. This study aims to develop an analytical method for the rapid determination of trace euonine and wilforidine in human plasma using HPLC coupled with APCI -MS (HPLC -APCI -MS). The present method is efficient in analyzing a large number of plasma samples obtained from pharmacokinetic studies.
Experimental

Chemicals and solvents
Euonine and wilforidine were isolated from a TW crude extract by using prepared HPLC techniques in our laboratory (17) . Their structures were characterized using HPLC -APCI-MS, 1 H nuclear magnetic resonance (NMR) and 13 C NMR. The purity of each compound reached . 97.5%, as determined by HPLC with an ultraviolet detector. Aconitine ( purity .99.5%; see structure in Figure 1 ) was collected from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and used as an internal standard (IS). HPLC-grade acetonitrile and acetic acid were purchased from Merck (Darmstadt, Germany). HPLC-grade ammonium acetate was obtained from Sigma (Steinheim, Germany). The solid-phase extraction cartridge [Oasisw mixed-mode cation-exchange (MCX), 50 mg/ 3 mL] used for sample preparation was procured from Waters (Milford, MA, USA). Ultrapure water (18.2 MV cm) was prepared on a Milli-Q integral water purification system (Millipore, Molsheim, France).
Blank human plasma samples were obtained from six healthy volunteers from Zhejiang Gongshang University (Hangzhou, Zhejiang, China) aged from 18 to 25 years. Plasma samples were obtained from five rheumatoid arthritis patient volunteers, treated in the Hangzhou Traditional Chinese Medical Hospital (Hangzhou, Zhejiang, China) for the disease and administered with TW tablets for .10 days. The five patient volunteers underwent physical examination and were given health consultation in advance.
Bremen, Germany) was used to control the HPLC -APCI-MS system and to process the data.
The separation was carried out on a Zorbax Plus Rapid Resolution High Definition (RRHD) C 18 column (50 mm Â 2.1 mm, 1.8 mm; Agilent Technologies, Wilmington, Delaware, USA) using 0.05% (v/v) acetic acid-ammonium acetate (5 mmol/L)/acetonitrile (30/70, v/v) as the mobile phase. The column oven was held at a constant temperature of 258C, and the autosampler temperature was maintained at 48C. The flow rate was 0.70 mL/min, and 10.0 mL of solution were injected into the LC-MS for the analysis.
Detection was performed on an Agilent LC-MSD Trap SL system equipped with an APCI source in the positive-ion mode. The optimized conditions of MS were as follows: m/z 500-1000 for scan range, 1 s for cycle time, 4.0 mA for corona current, 
Sample preparation
A simple protein precipitation method with acetonitrile was applied in the pretreatment of the QC samples, calibration standards and plasma samples. After the plasma was thawed and homogenized, 200 mL of plasma and 2.0 mL of IS (1.0 mg/L) were transferred using a micropipette into a 2.0-mL polypropylene centrifuge tube before analysis. Exactly, 1.0 mL of acetonitrile was used for extraction, and the tube was vortex-mixed by a Vortex-Genie-2 mixer and shaker for 5 min. After the solution was centrifuged at 7800 rpm for 5 min, the supernatant was shifted to a disposable glass tube, and operated again. The combined organic layers were acidified with 2.0 mL of 0.2% acetic acid and then loaded on an MCX cartridge previously conditioned with 1.0 mL of acetonitrile and 1.0 mL of deionized water in succession. The cartridge was then washed successively with 2.0 mL aliquots of deionized water and 1.0 mL of water/ acetonitrile (25/75, v/v). The alkaloids and IS were eluted from the cartridge with 10.0 g/L of aqueous ammonia in 1.0 mL of acetonitrile. The collected eluate was evaporated to dry under a stream of nitrogen and then dissolved in 0.2 mL aliquots of water/acetonitrile (30/70, v/v). Accurately, 10 mL aliquots were injected onto the HPLC-APCI/MS for analysis.
Selectivity
Six blank human plasma samples obtained from different sources were extracted as described above and checked for peaks that might interfere with the detection of euonine, wilforidine and IS in the plasma. The chromatographic peaks were verified by comparing the retention times (t R ) and the mass fragment ions with those of reference standards.
Matrix effect
To evaluate the matrix effect, an absolute matrix effect and a relative matrix effect based on the approach proposed by Matuszewski et al. (18) were calculated. In this paper, the absolute matrix effect was determined by comparing the mean peak areas of QC samples spiked after extraction (B) with those of the standard solutions (A). The values obtained in this study can be calculated as follows: absolute matrix effect (%) ¼ (B/A) Â 100. The relative matrix effect was evaluated on the plasma of six different healthy volunteers' for all tested analytes at three concentration levels (low, medium and high concentrations with 2.0, 15.0 and 50.0 mg/L, respectively) and three parallels by comparing the ratios of the responses of the analytes with the IS in different plasma samples via the postextraction spiked method. The relative matrix effect for the analyte was expressed as a relative standard deviation (RSD%) at each concentration level.
Precision and accuracy
Precision and accuracy were evaluated by analyzing the six replicates of QCs at four concentrations (0.5, 2.0, 15.0 and 50.0 mg/ L). For intraday precision, six aliquots were thawed for each of the QC samples (0.5, 2.0, 15.0 and 50.0 mg/L) and analyzed within a day. For interday precision, the experiments were repeated in triplicate for each of the QC samples on 8 separate days within a 2-week period. The RSD% of euonine and wilforidine concentrations measured in each QC sample was calculated. The acceptance criteria for precision were RSD% 20% for the lower limit of quantitation (LLOQ), and 15% for the others. Accuracy was expressed by the recoveries that were assessed by comparison of the mean peak area ratio obtained from plasma samples spiked before extraction (C) with those after pretreatment (B). The values obtained in this study can be calculated as recovery (%) ¼ (C/B) Â 100 (18) . Five replicate experiments were performed for each of the plasma samples at the concentration of 0.5, 2.0, 15.0 and 50.0 mg/L for the recovery.
Stability
The stability experiments were carried out to evaluate the analyte stability in human plasma samples under different conditions. Short-term stability was tested by placing the QC samples at room temperature in an autosampler for 12 h. Freeze-thaw stability was determined by analyzing the samples for three cycles (from 2208C to room temperature). The stability was then evaluated by comparing the concentration obtained with the nominal values.
Analysis of patient samples
Plasma samples were obtained from volunteer patients with rheumatoid arthritis treated with TW tablets daily for .10 days. For the determination of euonine and wilforidine, venous plasma was aliquoted to polypropylene tubes and stored at 2208C until analysis. The samples were prepared as described above and then subjected to HPLC -APCI/MS analysis.
Results and discussion
Sample preparation
Adjusting the chromatographic conditions and mass parameters, as well as developing an efficient extraction method, is necessary to obtain better extraction efficacy and less interference. In this paper, a variety of sample processing approaches including protein precipitation and liquid/liquid extraction with various solvents (e.g. methanol, acetonitrile, dichloromethane and ethyl acetate) were investigated. After the extraction and total processing time were comprehensively evaluated, a simple protein precipitation method was proposed for extraction. Acetonitrile was selected as the optimal protein precipitation solvent because of its good protein precipitation efficiency and good extraction efficiency.
Liquid chromatography and mass spectrometry Chromatographic separation of euonine, wilforidine and IS was carried out initially under isocratic conditions to develop a simple separation process within a short run time. Different columns, such as CLC C 8 (150 mm Â 5.0 mm Â 5.0 mm), Diamonsil C 18 (150 mm Â 4.6 mm Â 5.0 mm), XBridge Shield RP18 (250 mm Â 3.0 mm Â 5.0 mm), and Zorbax Plus RRHD C 18 (50 mm Â 2.1 mm Â 1.8 mm) as well as various mixtures of solvents using different buffers (ammonium acetate/acetate acid, and ammonium formate/formic acid) were tested to obtain ideal chromatographic separation. The results show that the Zorbax Plus RRHD C 18 column is the optimal selection for the separation of euonine, wilforidine and IS with a better peak shape, a shorter analysis time and a more suitable resolution.
The mobile phase is one of the important criteria in obtaining a good chromatographic separation with a desired response. Thus, the addition of a buffer [0.05% (v/v) acetic acid in 5 mmol/L ammonium acetate solution] to the mobile phase was proved to improve the optimum separation and to enhance the sensitivity under the positive APCI mode. The use of acetate buffer proved advantageous with respect to formate buffer for the isocratic separation and detection by APCI -MS in the positive mode for the determination of euonine, wilforidine and IS. In fact, a better chromatographic behavior and sensitivity were observed when using a mobile phase made up of the acetate buffer. In addition, under APCI optimized conditions, the peak heights for euonine, wilforidine and IS (10.0 mg/L) were .6 Â 10 3 by using acetate buffer, while they were only 3 Â 10 3 with formate buffer and 2 Â 10 3 without buffer in the mobile phase. Therefore, acetonitrile and a buffer of 0.05% (v/v) acetic acid in 5 mmol/L ammonium acetate solution (70:30, v/v) were finally selected as the mobile phase.
MS allows for optimization of the most abundant molecular ions by using either APCI or ESI with acquisition in the positive selected ion monitoring (SIM) mode; in addition, the APCI and ESI parameters (i.e., corona current, capillary voltage, drying gas flow and temperature, vaporizer gas flow and temperature) for euonine, wilforidine and IS were first optimized. Under optimized conditions, the signal intensities for euonine, wilforidine and IS (10.0 mg/L) were .6 Â 10 3 with the APCI interface, but were only 2 Â 10 3 with the ESI interface. The results show that the mass intensity with APCI is more sensitive than that with ESI. Under the selected APCI optimized conditions, the most sensitive signal with m/z at 806, 780 and 646 was observed and identified as [MþH] þ for euonine, wilforidine and IS (Figure 2 ), respectively. The best intensity for the [MþH] þ ion was found in the positive mode, because all euonine, wilforidine and IS were proton acceptors.
Selectivity
Under optimized LC and MS conditions, euonine, wilforidine and IS were separated with retention times of 4.08, 4.56 and 3.60 min, respectively (Figure 3) . To demonstrate the selectivity of the method, six blank human plasma and plasma spiked with the lowest standard (LLOQ) were extracted and injected for the Analysis of Euonine and Wilforidine by LC -APCI-MS 397 analysis. The representative chromatograms of a blank human plasma sample and a blank human plasma sample spiked with euonine, wilforidine (5.0 mg/L) and IS (10.0 mg/L) are shown in Figure 3 . No significant endogenous peaks were observed at the retention times of euonine, wilforidine and IS, and therefore, according to the guidance for industry bioanalytical method validation (2001) (19) , this developed method was selective.
Matrix effect
The data of matrix effect tests are presented in Table I . The absolute matrix effects of the analytes ranged from 82.2 to 93.1%. The relative matrix effects expressed as RSD% were between 4.4 and 9.6% for both euonine and wilforidine. The RSDs of the regression equation slopes in different plasma sources were 3.5 and 3.9% for euonine and wilforidine, respectively, which were below the suggested 4% limit of Matuszewski (20) . An absent or insignificant matrix effect in the different sources was confirmed by the results, which were in agreement with the requirement of the guidance for industry and bioanalytical method validation by the food and drug administration (19) .
Precision and accuracy
The results of the accuracy and precision are presented in Table II . The intraday RSDs for both euonine and wilforidine at 0.5, 2.0, 15.0 and 50.0 mg/L levels were in the range of 5.9 -8.2% and 5.7-8.7%, respectively, and the interday RSDs were in the range of 8.7 -12.9% and 8.8 -12.6%, respectively. The mean recoveries for both euonine and wilforidine (n ¼ 6) at four concentrations ranged from 85.4 to 101.0% and 92.0 to 97.5%, respectively. These data indicate that the repeatability and recovery of the assay are within the acceptance limits of +20% at LLOQ and +15% at the other concentration levels.
Linearity, lower limit of detection and LLOQ The calibration model was selected based on the analysis of the data by linear regression with intercepts and 1/x 2 weighting factor. The linear calibration curves were plotted by the peak area ratios of analyte to IS (Y) versus the target compound mass concentrations (C, mg/L). Representative linear equations for both euonine and wilforidine in plasma were summarized in Table III . Each standard point in every calibration curve was back calculated using its own equation. The linearities of the calibration curves were between 0.5 and 100.0 mg/L, and the correlation coefficient (r) for both euonine and wilforidine were !0.999.
The lower limits of detection (LLODs) were established on the basis of a signal-to-noise (S/N) ratio of 3, whereas the LLOQs were established on the basis of an S/N ratio of 10. The values of LLODs were estimated to be 0.2 mg/L for both euonine and wilforidine in plasma, as summarized in Table III . The values of LLOQs were 0.5 mg/L at the acceptable precision and accuracy based on 200 mL of plasma, as presented in Table III .
Stability
The data for the human plasma freeze -thaw cycle stability and short-term stability under room temperature at 0.5, 2.0, 15.0 and 50.0 mg/L levels of euonine and wilforidine in plasma are summarized in Table IV . No significant degradations (,7.2% for freeze -thaw cycle stability and ,8.4% for short-term stability under room temperature) were observed for euonine and wilforidine. The results show that euonine and wilforidine were stable under the investigated conditions as the measured concentrations were within acceptable limits ( 15% of the nominal concentrations).
Application to the real samples
The established HPLC-APCI/MS method has been used successfully for the quantification of both euonine and wilforidine in human plasma following oral administration in volunteer patients. The concentrations for euonine were 0.5, 2.6, 3.8, 7.4 and 0.5 mg/L, while for wilforidine they were 0.7, 1.8, 5.4, 5.6 and 0.8 mg/L. The representative SIM chromatograms of euonine and wilforidine from a volunteer patient are shown in Figure 4 . No interferences exist in the analysis of euonine and wilforidine in the human plasma sample.
Conclusions
The developed analytical method provides a sensitive, specific, accurate and precise quantification of euonine and wilforidine from human plasma using HPLC -APCI/MS under the SIM mode. The validated method allows for the determination of euonine and wilforidine ranging from 0.5 to 100.0 mg/L, and it is suitable to assess in detail the pharmacokinetics of euonine and wilforidine following the oral administration of therapeutic doses.
